

commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: January 27, 1998.

LaVerne Y. Stringfield,

Committee Management Office, NIH.

[FR Doc. 98-3099 Filed 2-6-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Open Meetings

Pursuant to Public Law 92-463, notice is hereby given of the following meetings of the Sleep Disorders Research Advisory Board, and its Education and Sleep Research Subcommittees, National Center on Sleep Disorders Research, National Heart, Lung, and Blood Institute.

Name of Meeting: Education Subcommittee.

Date: March 10, 1998.

Time: 1:00 p.m.-4:30 p.m.

Place: Natcher Building (45), Conference Room D, 45 Center Drive, Bethesda, Maryland 20892.

Purpose/Agenda: To discuss education related priorities and programs.

Name of Meeting: Sleep Research Subcommittee.

Date: March 10, 1998.

Time: 7:00 p.m.-10:00 p.m.

Place: Bethesda Hyatt Regency Hotel, Susquehanna/Severn Conference Room, One Bethesda Metro Center, Bethesda, Maryland 20892.

Purpose/Agenda: To review sleep research priorities and programs.

Name of Meeting: Sleep Disorders Research Advisory Board.

Date: March 11, 1998.

Time: 9:00 p.m.-4:00 p.m.

Place: Natcher Building (45), Conference Room D, 45 Center Drive, Bethesda, Maryland 20892.

Purpose/Agenda: To discuss recommendations on the implementation and evaluation of the National Center on Sleep Disorders Research programs.

Attendance by the public will be limited to space available.

Individuals who plan and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact the Executive Secretary in advance of the meeting.

Dr. James P. Kiley, Executive Secretary and Director, National Center on Sleep Disorders Research, NHLBI, Two Rockledge Center, Suite 10018, 6701 Rockledge Drive, MSC 7952, Bethesda, Maryland 20892-7952, (301) 435-0199, will furnish meeting and member information.

Dated: January 27, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-3100 Filed 2-6-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute on Drug Abuse (NIDA) Special Emphasis Panel meetings.

Purpose/Agenda: To review and evaluate grant applications.

Name of Committee: NIDA Special Emphasis Panel (Organization and Management of Drug Abuse Treatment Services).

Date: March 4, 1998.

Time: 8:30 a.m.

Place: Key Bridge Marriott Hotel, 1401 Lee Highway, Arlington, VA 22209.

Contact Person: Raquel Crider, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10-22, Telephone (301) 443-9042.

Name of Committee: NIDA Special Emphasis Panel (Strategic Program for Innovative Research on Cocaine (and other Psychomotor Stimulants) Addiction Pharmacotherapy).

Date: March 18-19, 1998.

Time: 8:30 a.m.

Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20852.

Contact Person: Khursheed Asghar, Ph.D., Scientific Review Administrator, Office of Extramural Program Review, National Institute on Drug Abuse, 5600 Fishers Lane, Room 10-22, Telephone (301) 443-2620.

The meetings will be closed in accordance with provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Numbers: 93.277, Drug Abuse Research Scientist Development and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for

Research Training; 93.279, Drug Abuse Research Programs)

Dated: January 30, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-3097 Filed 2-6-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel Meetings:

Name of Sep: ZDK1 GRB BC1.

Date: February 12, 1998.

Time: 3:00 pm.

Place: Room 6as-25S, Natcher Building, NIH (Telephone Conference Call).

Contact: Ned Feder, Ph.D., Review Branch, DEA, NIDDK, Natcher Building, Room 6as-25S, National Institutes of Health, Bethesda, Maryland 20892-6600, Phone: (303) 594-8890.

Purpose/Agenda: To review and evaluate contract proposals.

This notice is being published less than 15 days prior to the above meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

Name of Sep: ZDK1 GRB4 C1B.

Date: February 20, 1998.

Time: 3:00 pm.

Place: Room 6as-37A, Natcher Building, NIH (Telephone Conference Call).

Contact: William Elzinga, Ph.D., Review Branch, DEA, NIDDK, Natcher Building, Room 6as-37A, National Institutes of Health, Bethesda, Maryland 20892-6600, Phone: (301) 594-8895.

Purpose/Agenda: To Review and evaluate contract proposals.

These meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. (Catalog of Federal Domestic Assistance Program No. 93.847-849, Diabetes, Endocrine and Metabolic Diseases; Digestive Diseases and Nutrition; and Kidney Diseases, Urology and Hematology Research, National Institutes of Health)

Dated: February 2, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-3098 Filed 2-6-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Library of Medicine; Notice of Meeting of the Literature Selection Technical Review Committee

Pursuant to Public Law 92-463, notice is hereby given of a meeting of the Literature Selection Technical Review Committee, National Library of Medicine (NLM), on February 5-6, 1998, convening at 9 a.m. on February 5 and at 8:30 a.m. on February 6 in the Board Room of the National Library of Medicine, Building 38, 8600 Rockville Pike, Bethesda, Maryland.

The meeting on February 5 will be open to the public from 9 a.m. to approximately 10:30 a.m. for the discussion of administrative reports and program developments. Attendance by the public will be limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should contact Mrs. Lois Ann Colaianni at (301) 496-6921 two weeks before the meeting.

In accordance with provisions set forth in section 552b(c)(9)(B), Title 5 U.S.C., and section 10 of Public Law 92-463, the meeting will be closed on February 5 from 10:30 a.m. to approximately 5 p.m. and on February 6 from 8:30 a.m. to adjournment for the review and discussion of individual journals as potential titles to be indexed by the National Library of Medicine.

The presence of individuals associated with these publications is likely to significantly frustrate implementation of proposed action by NLM by hindering fair and open discussion and evaluation of individual journals by the Committee members.

This notice is being published less than 15 days prior to the meeting due to the urgent need to meet timing limitations imposed by the review and funding cycle.

Mrs. Lois Ann Colaianni, Scientific Review Administrator of the Committee, and Associate Director, Library Operations, National Library of Medicine, 8600 Rockville Pike, Bethesda, Maryland 20894, telephone number: (301) 496-6921, will provide a summary of the meeting, rosters of the

committee members, and other information pertaining to the meeting.

Dated: February 3, 1998.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 98-3093 Filed 2-6-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Method of Determining the Presence of Functional p53 in Mammalian Cells

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive world-wide license to practice the inventions embodied in U.S. Patent Applications SN 07/974,960; 08/288,872 which issued as U.S. Patent 5,616,463; 08/432,176 and corresponding foreign patent applications entitled, "Method of Determining the Presence of Functional p53 in Mammalian Cells" to Chrysallis Research Laboratories, San Francisco, CA. The patent rights in these inventions have been assigned to the United States of America and Johns Hopkins University.

The prospective exclusive license field of use may be limited to: FDA approved in-vitro diagnostic kit for cancer.

DATES: Only written comments and/or applications for a license which are received by NIH on or before May 11, 1998 will be considered.

ADDRESSES: Requests for copies of the patent applications, inquiries, comments and other materials relating to the contemplated licenses should be directed to: Joseph K. Hemby, Jr., J.D., Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; Telephone: (301) 496-7735 ext. 265; Facsimile: (301) 402-0220. A signed Confidentiality Agreement will be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective exclusive license may be granted unless within ninety (90) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The invention describes a specific gene, GADD45, whose expression is dependent on the presence of functional p53 in cells and tumors, as well as methods by which the presence of this gene may be detected. It also describes a diagnostic kit utilizing a nucleic acid sequence capable of binding functional p53, which is then measured to detect the presence of p53.

Applications for a license in the exclusive field of use filed in response to this notice will be treated as objections to the grant of the contemplated licenses. Comments and objections submitted to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: January 30, 1998

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 98-3101 Filed 2-6-98; 8:45 am]

BILLING CODE 4140-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Notice of Meetings

Pursuant to Public Law 92-463, notice is hereby given of the meetings of the Substance Abuse and Mental Health Services Administration's (SAMHSA's) Advisory Committee for Women's Services and Center for Substance Abuse Prevention's Drug Testing Advisory Board in February and March, 1998.

The meeting of the Advisory Committee for Women's Services will include a discussion of and update on policy and program issues relating to women's substance abuse and mental health service needs at SAMHSA, including the SAMHSA Fiscal Year 1998 budget and the President's Fiscal Year 99 budget; Knowledge Development and Application Grants; and future women's policy and program directions at SAMHSA.

Public comments are welcome. Please communicate with the individual listed